Pfizer, Inc and GlaxoSmithKline Plc.- Notable Market Players in Antibiotics Market
Antibiotics are powerful medicines that are used to fight against bacterial infections. Antibiotics are also known as antibacterial which include a range of powerful drugs and are used to treat diseases caused by bacteria.
Market leaders operating in the market have undertaken various organic growth strategies in the antibiotics market. The antibiotics market majorly consists of the players such as Sanofi., Novartis AG., Pfizer Inc, Bayer AG, Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, Astellas Pharma Inc , Abbott, Eli Lilly and Company among others. Several organic approaches, such as product launches, and expansion/relocation in the antibiotics Market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the Antibiotics market:
|
Year |
News |
|
Dec-2016 |
Pfizer Inc. announced that it has completed the acquisition of the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infective business, primarily outside the United States. The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam), the marketed agents Merrem/Meronem (meropenem) and Zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. |
|
May-2017 |
Pfizer’s lauched new antibiotic for multidrug resistant (MDR) infections – Zavicefta – in the UK and Germany, its first EU markets. |
|
July-2019 |
The company has launched an international research consortium to discover and develop new TB antibiotics in collaboration with eight biotechnology partners and European academic. |
|
September-2019 |
Astellas Pharma Inc.Announces Launch of Dafclir Tablets for the Treatment of Infectious Enteritis Caused by Clostridium difficile in Japan. It is likely to increase the action of selective antibacterial spectrum |
